Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.

Teruki IsobeTaku NaikiYosuke SugiyamaAya Naiki-ItoTakashi NagaiToshiki EtaniSatoshi NozakiKeitaro IidaYusuke NodaNobuhiko ShimizuNami TomiyamaRika BannoHiroki KubotaShuzo HamamotoRyosuke AndoNoriyasu KawaiTakahiro Yasui

Published in: International journal of clinical oncology (2021)

Second-line GD or PEM therapy for mUC patients showed equivalent survival benefits. GNRI and NLR are prognostic biomarkers for survival outcome.

Keyphrases

end stage renal disease
newly diagnosed
prognostic factors
free survival
clinical trial
squamous cell carcinoma
advanced non small cell lung cancer
patient reported
drug administration